COMPASS Pathways plc (CMPS)

NMS – Real vaqt narxi. Valyuta: USD

14.22

+0.84 (6.28%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

14.27

+0.05 (0.34%)

Bozordan keyin: Aug 12, 2026, 4:44 PM EDT

12.08.2026

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

Compass Pathways NASDAQ: CMPS said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027.

06.08.2026

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event wil.

06.08.2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-trauma.

05.08.2026

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of emp.

05.08.2026

COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript

05.08.2026

Compass Pathways Q2 Earnings Call Highlights

Compass Pathways NASDAQ: CMPS said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following positive Phase III results and six-month durability data from two trials.

05.08.2026

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 financial results and business highlights. “The first half of 2026 marked a defining period for Compass as we continued to build momentum across clinical, regulatory and commercial fronts in preparation for the potential approval and launch of COMP360,” said Kabir.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

06.08.2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-trauma.

05.08.2026

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of emp.

05.08.2026

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 financial results and business highlights. “The first half of 2026 marked a defining period for Compass as we continued to build momentum across clinical, regulatory and commercial fronts in preparation for the potential approval and launch of COMP360,” said Kabir.

COMPASS Pathways plc (CMPS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

COMPASS Pathways plc (CMPS)

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript

Compass Pathways Q2 Earnings Call Highlights

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Videolar

No Data

Press-relizlar

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript

Compass Pathways Q2 Earnings Call Highlights

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Videolar

No Data

Press-relizlar

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Search stocks

COMPASS Pathways plc (CMPS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

COMPASS Pathways plc (CMPS)

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript

Compass Pathways Q2 Earnings Call Highlights

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Videolar

No Data

Press-relizlar

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript

Compass Pathways Q2 Earnings Call Highlights

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Videolar

No Data

Press-relizlar

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights